Kyverna Therapeutics (KYTX) Depreciation & Amortization (CF) (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Depreciation & Amortization (CF) of $351000.0 for Q1 2026, down 4.62% on a QoQ basis from $368000.0 in Q4 2025, and down 29.94% year-over-year from $501000.0 in Q1 2025.
Kyverna Therapeutics (KYTX) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $351000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 29.94% year-over-year to $351000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 23.37% YoY) and the FY2025 annual result came in at $1.8 million, down 15.66% from the prior year.
- Depreciation & Amortization (CF) was $351000.0 for Q1 2026 at Kyverna Therapeutics, down from $368000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $563000.0 in Q4 2024 and bottomed at $351000.0 in Q1 2026.
- A 4-year average of $460769.2 and a median of $462000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) climbed 28.33% — and 2025, when it plunged 34.64%.
- Kyverna Therapeutics' Depreciation & Amortization (CF) stood at $462000.0 in 2023, then increased by 21.86% to $563000.0 in 2024, then plunged by 34.64% to $368000.0 in 2025, then dropped by 4.62% to $351000.0 in 2026.
- Business Quant data shows KYTX's Depreciation & Amortization (CF) at $351000.0 in Q1 2026, $368000.0 in Q4 2025, and $415000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - | 351,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 351,000.00 |
| Mar 31, 2026 | 351,000.00 |
| Dec 31, 2025 | 368,000.00 |
| Dec 31, 2025 | 368,000.00 |
| Sep 30, 2025 | 415,000.00 |
| Sep 30, 2025 | 415,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Mar 31, 2025 | 501,000.00 |
| Mar 31, 2025 | 501,000.00 |
| Dec 31, 2024 | 563,000.00 |
| Dec 31, 2024 | 563,000.00 |
| Sep 30, 2024 | 558,000.00 |
| Sep 30, 2024 | 558,000.00 |
| Jun 30, 2024 | 530,000.00 |
| Jun 30, 2024 | 530,000.00 |
| Mar 31, 2024 | 482,000.00 |
| Mar 31, 2024 | 482,000.00 |
| Dec 31, 2023 | 462,000.00 |
| Dec 31, 2023 | 462,000.00 |